A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Once-daily Inhaled Fluticasone Furoate on the Hypothalamic-pituitary-adrenocortical Axis of Children with Asthma

Overview

Journal Allergy Asthma Clin Immunol

Specialty Allergy & Immunology

Date 2020 Feb 12

PMID 32042286

Authors

Philippe Bareille

Susan Tomkins

Varsha Imber

Mohammed Tayob

Karen Dunn

Rashmi Mehta

Sanjeev Khindri

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the effects of fluticasone furoate on the hypothalamic-pituitary-adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma.

Methods: This was a randomized, double-blind, placebo-controlled, multicenter, stratified, parallel-group, non-inferiority study of fluticasone furoate 50 µg inhalation powder administered once daily. The study enrolled children (aged 5-11 years inclusive) with a documented diagnosis of asthma for ≥ 6 months and a Childhood Asthma Control Test score of > 19. After a 7-14-day run-in period, eligible subjects were stratified by age and randomized to fluticasone furoate 50 µg once daily or placebo once daily via ELLIPTA for 6 weeks. The primary endpoint was the change from baseline (expressed as a ratio) in 0-24-h weighted mean serum cortisol at the end of the treatment period.

Results: Fifty-six randomized subjects received fluticasone furoate 50 µg once daily and 55 received placebo. The primary analysis was performed in the serum cortisol population (n = 104) and demonstrated that fluticasone furoate 50 µg once daily was non-inferior to placebo (ratio = 0.93; 95% confidence interval 0.8096, 1.0620), as the lower limit of the 95% confidence interval for the geometric mean treatment ratio of fluticasone furoate 50 µg once daily versus placebo was greater than 0.80. Findings from the intent-to-treat population (n = 111) were similar.

Conclusions: Six weeks of treatment with inhaled fluticasone furoate 50 µg once daily had no clinically relevant effect on the hypothalamic-pituitary-adrenocortical axis function of children, as measured by 24-h serum cortisol profiles. The primary analysis showed that fluticasone furoate 50 µg once daily was non-inferior to placebo. Fluticasone furoate 50 µg once daily was well tolerated and no new safety concerns emerged during the study.

Trial Registration: This study is registered in ClinicalTrials.gov (NCT02483975). Date of submission: 25 June 2015.

References

Oliver A, Covar R, Goldfrad C, Klein R, Pedersen S, Sorkness C . Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma. J Pediatr. 2016; 178:246-253.e2. DOI: 10.1016/j.jpeds.2016.08.010. View

Brown P, Blundell G, Greening A, Crompton G . Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med. 1991; 85(6):511-6. DOI: 10.1016/s0954-6111(06)80269-6. View

Lipworth B . Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999; 159(9):941-55. DOI: 10.1001/archinte.159.9.941. View

Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N . Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf). 2000; 52(5):633-40. DOI: 10.1046/j.1365-2265.2000.00984.x. View

Charmandari E, Nicolaides N, Chrousos G . Adrenal insufficiency. Lancet. 2014; 383(9935):2152-67. DOI: 10.1016/S0140-6736(13)61684-0. View

Allen A . The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet. 2013; 52(10):885-96. PMC: 3779313. DOI: 10.1007/s40262-013-0078-1. View

Todd G, Acerini C, Ross-Russell R, Zahra S, Warner J, McCance D . Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002; 87(6):457-61. PMC: 1755820. DOI: 10.1136/adc.87.6.457. View

Mortimer K, Tata L, Smith C, West J, Harrison T, Tattersfield A . Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax. 2006; 61(5):405-8. PMC: 2111185. DOI: 10.1136/thx.2005.052456. View

Oliver A, Allen A, VanBuren S, Hamilton M, Tombs L, Kempsford R . Safety, tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate, a novel inhaled corticosteroid, in children aged 5-11 years with persistent asthma: A randomized trial. Clin Pharmacol Drug Dev. 2016; 3(2):144-50. DOI: 10.1002/cpdd.82. View

10.

Smith R, Downey K, Gordon M, Hudak A, Meeder R, Barker S . Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled corticosteroid. Paediatr Child Health. 2013; 17(5):e34-9. PMC: 3381924. DOI: 10.1093/pch/17.5.e34. View

11.

Agwu J, Spoudeas H, Hindmarsh P, Pringle P, Brook C . Tests of adrenal insufficiency. Arch Dis Child. 1999; 80(4):330-3. PMC: 1717897. DOI: 10.1136/adc.80.4.330. View

12.

Zollner E, Lombard C, Galal U, Hough F, Irusen E, Weinberg E . Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children. Pediatrics. 2012; 130(6):e1512-9. DOI: 10.1542/peds.2012-1147. View

13.

Kapadia C, Nebesio T, Myers S, Willi S, Miller B, Allen D . Endocrine Effects of Inhaled Corticosteroids in Children. JAMA Pediatr. 2016; 170(2):163-70. DOI: 10.1001/jamapediatrics.2015.3526. View

14.

Woods C, Argese N, Chapman M, Boot C, Webster R, Dabhi V . Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. Eur J Endocrinol. 2015; 173(5):633-42. PMC: 4588051. DOI: 10.1530/EJE-15-0608. View

15.

Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A . Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clin Ther. 2014; 36(6):928-939.e1. DOI: 10.1016/j.clinthera.2014.03.014. View

16.

Bondugulapati L, Rees D . Inhaled corticosteroids and HPA axis suppression: how important is it and how should it be managed?. Clin Endocrinol (Oxf). 2016; 85(2):165-9. DOI: 10.1111/cen.13073. View

17.

Raff H, Sharma S, Nieman L . Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol. 2014; 4(2):739-69. PMC: 4215264. DOI: 10.1002/cphy.c130035. View

18.

Henzen C, Suter A, Lerch E, Urbinelli R, Schorno X, Briner V . Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000; 355(9203):542-5. DOI: 10.1016/S0140-6736(99)06290-X. View

19.

Zollner E . Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids: part 1. Which test should be used?. Pediatr Allergy Immunol. 2007; 18(5):401-9. DOI: 10.1111/j.1399-3038.2007.00540.x. View

20.

Lipworth B, Seckl J . Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997; 52(5):476-82. PMC: 1758571. DOI: 10.1136/thx.52.5.476. View